Imatinib Zentiva

Imatinib mesylate, the active ingredient in Imatinib Zentiva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor in adult patients. GNH USA supplies Imatinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib Zentiva targets malignant cells driven by specific kinase pathways and is employed in the following approved indications: - Chronic myeloid leukemia: reduces leukemic cell proliferation and improves long‑term survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: induces remission by blocking BCR‑ABL signaling. - Gastrointestinal stromal tumor: inhibits c‑KIT and PDGFR to control tumor growth.

Imatinib Zentiva may cause a range of adverse reactions. Most are mild to moderate, but serious events can occur.

Common Side Effects: - Nausea - Edema (peripheral swelling) - Muscle cramps or pain - Fatigue - Diarrhea - Rash or skin irritation

Serious or Rare Side Effects: - Severe neutropenia or leukopenia - Hepatotoxicity (elevated liver enzymes, hepatitis) - Cardiac failure or reduced left‑ventricular function - Pulmonary arterial hypertension - Severe skin reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis) - Tumor lysis syndrome

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts: perform regular complete blood counts to detect cytopenias. - Assess liver function: check transaminases and bilirubin periodically. - Evaluate cardiac status: monitor for signs of heart failure or reduced ejection fraction. - Avoid use in patients with known hypersensitivity: discontinue if allergic reaction occurs. - Pregnancy: discuss potential risks with the prescriber; safety not established. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Imatinib Zentiva can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic exposure. - Antacids containing aluminum or magnesium: may decrease oral absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect and raise INR. - Phenytoin: may alter imatinib levels, requiring dose adjustment. - Concomitant use with other tyrosine kinase inhibitors: may increase risk of overlapping toxicities.